Media contacts: For an embargoed PDF, please contact Angela Collom at acollom ... (FIT), colonoscopies or multitarget stool DNA test (Exact Sciences Cologuard) vs. four emerging screening methods ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... 1.2 million patients including a record number with Cologuard and Etty DX. Growing total revenue 13% ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.